

MARKET RELEASE

MedAdvisor adjusts price for capital raise, targeting \$45 million to acquire Adheris Health

Melbourne, Australia, 6 November, 2020 - MedAdvisor Limited (**MedAdvisor**) (ACN 145 327 617, ASX: MDR) has adjusted the price for the capital raise as it forges ahead to acquire US-based Adheris Health.

The feedback this week on MedAdvisor's acquisition of Adheris Health from investors has been overwhelmingly supportive based on the strategic alignment to the MedAdvisor business and the scale opportunity that it offers the company in the US market, which represents approximately 40% of the entire global medications market.

Whilst there was strong support at a price premium on MedAdvisor's last close to 45 cents, including the company's largest shareholder HMS, it became clear through the engagement process this week that there was stronger support at a 5% discount to the company's last close of 40 cents.

As a result, MedAdvisor has elected to price the deal at 38 cents which is expected to allow the company to attract a broader cohort of new strategic investors to the register.

The maximum amount that MedAdvisor may raise under the Placement is approximately AUD \$23.5M. The maximum amount that MedAdvisor may raise under the Entitlement Offer is approximately AUD \$37.7M.

The targeted amount to be raised under the Placement and Entitlement Offer is AUD \$45.0M, with a minimum amount of AUD \$35.0M to be raised under the Placement and Institutional Entitlement Offer.

The maximum amount that MedAdvisor may raise under the Institutional Entitlement Offer is approximately AUD \$16.7M. MedAdvisor may raise up to AUD \$21.0M under the Retail Entitlement Offer if shareholders take up their entitlements in full. Shareholders will also be able to subscribe for additional shares under the Retail Entitlement Offer.

Offer timetable

An indicative timetable of the key dates in respect of the Entitlement Offer is set out below:

Announcement of Acquisition and Offer. MedAdvisor enters back-to-back trading halt with two additional days of voluntary suspension.	Monday, 2 November 2020
Institutional Entitlement Offer and bookbuild commences	Friday, 6 November 2020
MedAdvisor comes out of suspension and announces results of Placement and Institutional Entitlement Offer (before market opens)	Tuesday, 10 November 2020
Record Date for participation in Entitlement Offer	7.00pm (AEST) Tuesday, 10 November 2020
Retail Entitlement Offer opens and despatch of Retail Offer Booklet	Friday, 13 November 2020
Settlement of placement and institutional entitlement Offer	Friday, 13 November 2020
Closing of Acquisition and issue of convertible	Monday, 16 November 2020
Allotment of Placement and Institutional Entitlement Offer shares	Monday, 16 November 2020
Despatch of Notice of Annual General Meeting	Friday, 20 November 2020
Retail Entitlement Offer closes	Friday, 27 November 2020
Settlement of Retail Entitlement Offer	Wednesday, 2 December 2020
Allotment of Retail Entitlement Offer shares	Friday, 4 December 2020
Normal trading resumes on all shares	Monday, 7 December 2020
Annual General Meeting *	Monday, 21 December 2020

Note: the timetable above is indicative only and may be subject to change. MedAdvisor reserves the right to amend any or all of these dates and times without notice, subject to the *Corporations Act 2001* (Cth) and the ASX Listing Rules and other applicable laws. In particular, MedAdvisor reserves the right to extend the closing date of the Retail Entitlement Offer, to accept late applications under the Retail Entitlement Offer (either generally or in particular cases) and to withdraw the Entitlement Offer without prior notice. Any extension of the closing date will have a consequential effect on the issue date of New Shares.

Further information

Further details of the Acquisition and the Offer are set out in the replacement investor presentation also provided to the ASX today. The Investor Presentation contains important information including key risks and foreign selling restrictions with respect to the Entitlement Offer.

If you have any questions, you should seek advice from your stockbroker, accountant or other independent and appropriately licensed professional advisor.

For further information about the Entitlement Offer, you can call the MedAdvisor shareholder information line on +61 2 9241 6199 at any time between 9.00am and 4.30pm (AEST) on Monday to Friday.

- ENDS -

For more information:

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Alex Beashel
Corporate Communications
ab@alexbeashel.com
+61 466 308 667

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.7 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100.

Carlo Campiciano - Company Secretary
MedAdvisor Limited
(ACN 145 327 617)
Level 2
971 Burke Road
Camberwell Vic 3124